From: Widespread pain in axial spondyloarthritis: clinical importance and gender differences
Variables | Total group (n = 170) | Men (n = 108) | Women (n = 62) |  | |||
---|---|---|---|---|---|---|---|
Mean (SD) | Med (IQR) | Mean (SD) | Med (IQR) | Mean (SD) | Med (IQR) | p Value | |
Age, yr | 42.9 (12.2) | 42.7 (20.3) | 43.8 (12.5) | 43.2 (20.4) | 41.3 (11.5) | 42.1 (18.0) | .199 |
Disease duration, yr | 13.1 (11.1) | 10.7 (16.6) | 14.0 (11.2) | 11.9 (18.4) | 11.5 (11.0) | 8.8 (13.0) | .155 |
Height, cm | 171.6 (9.4) | 172.3 (12.9) | 176.2 (7.1) | 176.2 (9.1) | 163.7 (7.4) | 163.4 (9.5) | < .00 |
Weight, kg | 77.0 (15.0) | 76.6 (20.9) | 81.7 (13.9) | 80.5 (19.2) | 69.7 (13.4) | 67.0 (18.1) | < .00 |
BMI, kg/m2 | 26.1 (4.4) | 25.6 (6.4) | 26.3 (4.4) | 25.5 (6.1) | 25.7 (4.4) | 25.7 (7.1) | .408 |
BASDAI (0–10) | 3.8 (2.1) | 3.7 (3.3) | 3.6 (2.2) | 3.5 (3.5) | 4.3 (2.0) | 4.2 (3.1) | .027 |
PGDA (0–10) (n = 146) | 1.4 (1.8) | 1.0 (2.0) | 1.4 (1.9) | 0.9 (2.0) | 1.4 (1.6) | 1.0 (1.6) | .583 |
CRP, mg/L (n = 141) | 8.3 (16.0) | 2.9 (6.6) | 8.9 (16.5) | 3.0 (6.6) | 7.4 (15.3) | 2.2 (6.7) | .810 |
BASFI (0–10) | 3.6 (2.4) | 3.4 (3.8) | 3.5 (2.4) | 3.2 (4.0) | 3.8 (2.3) | 3.7 (3.7) | .459 |
BASMI (0–10) | 3.0 (1.8) | 2.8 (2.0) | 3.3 (2.0) | 2.8 (2.8) | 2.6 (1.2) | 2.6 (1.6) | .002 |
Cervical rotation, degrees | 60.5 (19.6) | 65.0 (25.0) | 58.0 (21.3) | 62.5 (27.8) | 65.0 (15.6) | 66.0 (20.5) | .015 |
Tragus to wall, cm | 13.6 (4.6) | 11.7 (4.5) | 14.9 (5.0) | 13.3 (6.2) | 11.4 (2.3) | 10.8 (1.8) | < .00 |
Lateral flexion, cm | 12.4 (5.1) | 12.7 (8.1) | 11.7 (6.1) | 12.1 (9.4) | 13.5 (4.2) | 13.1 (6.1) | .028 |
Intermalleolar distance, cm | 99.0 (22.6) | 103.3 (25.1) | 101.0 (21.4) | 105.2 (25.2) | 95.5 (24.2) | 100.7 (25.0) | .141 |
Modified Schober, cm | 5.3 (2.1) | 5.5 (2.5) | 4.9 (2.3) | 5.2 (3.1) | 5.9 (1.7) | 6.2 (2.0) | .002 |
TSK-11 (11–44) | 24.8 (6.3) | 25.0 (10.0) | 27.8 (6.4) | 25.0 (10.0) | 24.9 (6.0) | 25.0 (9.3) | .888 |
HADS depression (0–21) | 4.6 (3.6) | 4.0 (5.0) | 4.8 (3.7) | 4.0 (5.0) | 4.4 (3.5) | 3.0 (4.0) | .580 |
HADS anxiety (0–21) | 7.1 (3.6) | 7.0 (5.0) | 6.7 (3.4) | 7.0 (5.0) | 7.8 (3.9) | 7.5 (5.0) | .071 |
Frequencies (%) | |||||||
Gender, male/female | 108/62 (64/36) | NA | NA | NA | |||
NSAIDs, yes/no | 87/83 (51/49) | 56/52 (52/48) | 31/31 (50/50) | .816 | |||
Biologicals, yes/no | 67/103 (39/61) | 45/63 (42/58) | 22/40 (36/64) | .427 | |||
Corticosteroids, yes/no | 12/158 (7/93) | 6/102 (6/94) | 6/56 (10/90) | .313a | |||
DMARDs, yes/no | 71/99 (42/58) | 43/65 (40/60) | 28/34 (45/55) | .496 | |||
Psychopharmacologic agents, yes/no | 12/158 (7/93) | 6/102 (6/94) | 6/56 (10/90) | .313a | |||
Analgesics, yes/no | 73/97 (43/57) | 33/75 (31/69) | 40/22 (65/35) | < .00 | |||
Work status, yes/nob | 99/64 (61/39) | 64/38 (63/37) | 35/26 (57/43) | .497 |